Company profile for Swedish Orphan Biovitrum AB

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Sobi is an international biopharmaceutical company focused on rare diseases. We are dedicated to providing access to innovative treatments that transform life for people with rare diseases. We focus on two therapeutic areas – Haematology and Immunology – and also have a portfolio of Specialty Care products. Within Haematology, we have become a leading company in haemophilia, where we seek to shape new standards, optimise t...
Sobi is an international biopharmaceutical company focused on rare diseases. We are dedicated to providing access to innovative treatments that transform life for people with rare diseases. We focus on two therapeutic areas – Haematology and Immunology – and also have a portfolio of Specialty Care products. Within Haematology, we have become a leading company in haemophilia, where we seek to shape new standards, optimise treatment, build evidence, create sustainable access and provide community support in haemophilia care. Our Immunology portfolio, with three strongly growing products that each meet high unmet medical needs.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Sweden
Address
Address
Tomtebodavägen 23A Solna
Telephone
Telephone
+46(0)8 697 20 00
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/sobi-to-showcase-scientific-advances-and-commitment-to-haematology-at-ash-2025-302634280.html

PR NEWSWIRE
05 Dec 2025

https://www.pharmiweb.com/press-release/2025-12-04/the-new-england-journal-of-medicine-publishes-positive-phase-3-valiant-results-of-pegcetacoplan-for-c3g-and-primary-ic-mpgn

PHARMIWEB
04 Dec 2025

https://www.prnewswire.com/news-releases/clinically-meaningful-pivotal-study-results-for-olezarsen-in-shtg-presented-as-a-late-breaker-at-aha-scientific-sessions-302609346.html

PR NEWSWIRE
08 Nov 2025

https://www.globenewswire.com/news-release/2025/10/25/3174168/0/en/Data-presented-at-ACR-Convergence-2025-highlight-Sobi-s-commitment-to-advancing-care-across-rare-and-underserved-inflammatory-conditions.html

GLOBENEWSWIRE
25 Oct 2025

https://www.prnewswire.com/news-releases/sobi-showcases-new-data-across-rare-inflammatory-conditions-at-acr-2025-302593848.html

PR NEWSWIRE
24 Oct 2025

https://www.prnewswire.com/news-releases/sobi-announces-revised-full-year-outlook-and-advances-publication-of-the-q3-2025-financial-report-302588429.html

PR NEWSWIRE
20 Oct 2025

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty